2017 Immuno-Oncology Symposium

Holger N. Lode, University Medicine Greifswald, presenting Abstract #111, "Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms"

Orlando, FL - 2017 Clinical Immuno-Oncology Symposium - Holger N. Lode, University Medicine Greifswald, presenting Abstract #111, "Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms," during Oral Abstract Session C at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium here today, Saturday, February 25, 2017. The conference, which is a collaboration between the American Society of Clinical Oncology and Society for Immunotherapy of Cancer, is focused on clinical and translational research in immuno-oncology and the implications for clinical care. Photo by © ASCO/Luke Franke 2017